Global Myelodysplastic Syndrome Market 2015-2019 Examines Rise in Aging Population / Use of Off-Label Drugs/ Rise in Public Awareness

Feb 15, 2016, 08:10 ET from Research and Markets

DUBLIN, Feb. 15, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/hwgmxm/global) has announced the addition of the "Global Myelodysplastic Syndrome Market 2015-2019" report to their offering.

The global myelodysplastic syndrome market to grow at a CAGR of 9.93% during the period 2015-2019.

Global Myelodysplastic Syndrome Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome market for 2015-2019. To calculate the market size, we consider revenue generated from the sales of various drugs used for treating myelodysplastic syndrome.

Government organizations and pharmaceutical companies are conducting awareness programs to spread knowledge about the disease and associated drugs. In addition, they are also providing patient assistance programs to give low-income people with myelodysplastic syndrome access to these drugs. These two factors will surge the number of people availing treatment services, increasing the sales and consumption of drugs.

According to the report, the immune system of an individual deteriorates as aging progresses. For this reason, people aged 60 and above are more susceptible to this disease. A surge in the population of this age group will increase the need for treatment drugs, positively influencing the latter's sales and revenue.

Further, the report states that the high cost of drugs used for treating myelodysplastic syndrome can deter people from consuming them.

Key vendors

  • Celgene
  • Novartis
  • Otsuka

Other prominent vendors

  • Acceleron Pharma
  • Amgen
  • Astellas
  • Astex
  • Actinium Pharmaceuticals
  • Bellicum Pharmaceuticals
  • BioLineRx
  • Celator Pharmaceuticals
  • Cornerstone Pharmaceuticals
  • CTI BioPharma
  • Eli Lilly
  • Gamida Cell
  • GlaxoSmithKline
  • KaloBios Pharmaceuticals
  • Kiadis Pharma
  • Mirati Therapeutics
  • Onconova Therapeutics
  • Strategia Therapeutics
  • Sumitomo Dainippon Pharma
  • Sunesis Pharmaceuticals
  • Targazyme
  • TetraLogic Pharmaceuticals

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Product profile

Part 04: Market research methodology

Part 05: Introduction

Part 06: Disease overview

Part 07: Pipeline portfolio

Part 08: Market landscape

Part 09: Market segmentation by drug class

Part 10: Market segmentation by route of administration

Part 11: Geographical Segmentation

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Part 17: Vendor landscape

PART 18: Key vendor analysis

PART 19: Appendix

For more information visit http://www.researchandmarkets.com/research/hwgmxm/global

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com